Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ilodecakin - ARMO Biosciences/Merck & Co

Next Previous
X
Search
Drug Profile

Ilodecakin - ARMO Biosciences/Merck & Co

Alternative Names: AM 0010; LY-3500518; PEG-ilodecakin; PEG-rHuIL-10; Pegilodecakin - ARMO Biosciences/Merck & Co; PEGylated Human IL-10; PEGylated Interleukin-10; PEGylated recombinant human Interleukin-10

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer ARMO Biosciences
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Interleukins; Polyethylene glycols
  • Mechanism of Action Interleukin 10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
  • Discontinued Fibrosis; Hypercholesterolaemia; Inflammatory bowel diseases

Most Recent Events

  • 02 Jan 2023 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Recurrent) in USA (SC) (NCT03382899)
  • 02 Jan 2023 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT03382912)
  • 02 Jan 2023 No development reported - Phase-III for Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia, Austria, Belgium, Canada, Germany, France, Italy, South Korea, Spain, Taiwan, United Kingdom, Poland, USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top